Literature DB >> 11536246

Direct correlation between human herpesvirus-8 seroprevalence and classic Kaposi's sarcoma incidence in Northern Sardinia.

R Santarelli1, R De Marco, M V Masala, A Angeloni, S Uccini, R Pacchiarotti, M A Montesu, R Satta, D Cerimele, A Faggioni, F Cottoni.   

Abstract

The human herpesvirus-8 (HHV-8) has been associated with the development of Kaposi's sarcoma. A high incidence of classic Kaposi's sarcoma has been described in Sardinia, an island West of Italy's mainland. Different seroepidemiological analyses have reported that prevalence of HHV-8 infection varies worldwide: a high HHV-8 seroprevalence has been shown in Italy. The present survey was carried out to evaluate the correlation between HHV-8 infection and classic Kaposi's sarcoma incidence in northern Sardinia. Blood samples were collected from 226 healthy donors born and resident in five different areas of North Sardinia. Seroprevalence to HHV-8 was determined searching antibodies to viral lytic proteins by immunofluorescence in sera diluted at 1:10. Classic Kaposi's sarcoma incidence data spanning a period of 23 years were examined in the areas studied. The present screening revealed that seroprevalence was 35%, within a range of 15.3-46.3% in the five areas, although it should be considered that the seroprevalence to HHV-8 can be established more accurately by the combined use of different assays. Age emerged as an important risk factor. Indeed, subjects aged > 50 years showed a higher seroprevalence to HHV-8 as compared with younger individuals. A strong direct correlation between HHV-8 prevalence and classic Kaposi's sarcoma incidence has been also observed. The wide diffusion of HHV-8 in Sardinia appears to represent an important factor in the high incidence of classic Kaposi's sarcoma reported in the island. However, additional co-factors, such as age, sex, genetic traits, or viral strain pathogenicity, are likely to play a role in the development of the disease. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11536246     DOI: 10.1002/jmv.2043

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  Scrotal Kaposi's Sarcoma in HIV-negative patient: A case report and review of the literature.

Authors:  Mustafa Gürkan Yenice; Esra Varnalı; Kamil Gökhan Şeker; Ayşe Kavak; Volkan Tuğcu
Journal:  Turk J Urol       Date:  2017-12-11

2.  CD4+ and CD8+ T-cell skewness in classic Kaposi sarcoma.

Authors:  Antonio Galleu; Claudio Fozza; Maria Pina Simula; Salvatore Contini; Patrizia Virdis; Giovanna Corda; Simonetta Pardini; Francesca Cottoni; Sara Pruneddu; Antonio Angeloni; Simona Ceccarelli; Maurizio Longinotti
Journal:  Neoplasia       Date:  2012-06       Impact factor: 5.715

Review 3.  Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis.

Authors:  Lyubomir A Dourmishev; Assen L Dourmishev; Diana Palmeri; Robert A Schwartz; David M Lukac
Journal:  Microbiol Mol Biol Rev       Date:  2003-06       Impact factor: 11.056

4.  Isolated Kaposi Sarcoma in two HIV negative patients.

Authors:  Iman Seleit; Abdalla Attia; Alaa Maraee; Rehab Samaka; Ola Bakry; Emad Eid
Journal:  J Dermatol Case Rep       Date:  2011-06-06

5.  Mortality among HIV-1- and human herpesvirus type 8-affected mother-infant pairs in Zambia.

Authors:  Janet Wojcicki; Mulindi Mwanahamuntu; Veenu Minhas; Boris Djokic; Chipepo Kankasa; Winslow Klaskala; Brad Brayfield; Saul Phiri; Charles Wood; Charles D Mitchell
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

6.  Classic Kaposi's sarcoma in Italy, 1985-1998.

Authors:  L Dal Maso; J Polesel; V Ascoli; P Zambon; M Budroni; S Ferretti; R Tumino; G Tagliabue; S Patriarca; M Federico; M Vercelli; A Giacomin; G Vicario; F Bellù; F Falcini; E Crocetti; V De Lisi; S Vitarelli; S Piffer; F Stracci; D Serraino; G Rezza; S Franceschi
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.